Antineoplastics
1
Reactions 1413 - 4 Aug 2012 S Antineoplastics Haematological toxicities: 7 case reports Seven women aged 31–82 years received erlotinib or gefitinib in combination with one or more cytotoxic drugs [routes, dosages, and durations of treatment to reaction onset not stated] for lung cancer and developed grade 3-4 adverse events [see table]. Patient characteristics Patient/sex/ Drugs (number of Grade 3-4 adverse age (y) cycles) reactions 1/F/82 erlotinib, anaemia gemcitabine (2) 2/F/82 erlotinib, leucopenia, pemetrexed (2) neutropenia, anaemia 3/F/75 erlotinib, leucopenia, neutropenia pemetrexed (1) 4/F/75 gefitinib, carboplatin, neutropenia, pemetrexed (6) thrombocytopenia, anaemia 5/F/69 erlotinib, carboplatin, leucopenia docetaxel (2) 6/F/76 erlotinib, docetaxel (2) neutropenia, leucopenia, anaemia 7/F/31 gefitinib, docetaxel (3) leucopenia The regimen was changed in patients 1–3 [other treatments not stated; outcomes not stated]. Author comment: "Concerning adverse events of grade 3 or higher, they were all hematotoxicity". Hirano S, et al. Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI. Gan to Kagaku Ryoho 39: 213-219, No. 2, Feb 2012 [Japanese; summarised from a translation] - Japan 803074505 1 Reactions 4 Aug 2012 No. 1413 0114-9954/10/1413-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1413 - 4 Aug 2012
SAntineoplastics
Haematological toxicities: 7 case reportsSeven women aged 31–82 years received erlotinib or
gefitinib in combination with one or more cytotoxic drugs[routes, dosages, and durations of treatment to reactiononset not stated] for lung cancer and developed grade 3-4adverse events [see table].
Patient characteristicsPatient/sex/ Drugs (number of Grade 3-4 adverseage (y) cycles) reactions
1/F/82 erlotinib, anaemiagemcitabine (2)
2/F/82 erlotinib, leucopenia,pemetrexed (2) neutropenia, anaemia
3/F/75 erlotinib, leucopenia, neutropeniapemetrexed (1)
4/F/75 gefitinib, carboplatin, neutropenia,pemetrexed (6) thrombocytopenia,
anaemia5/F/69 erlotinib, carboplatin, leucopenia
docetaxel (2)6/F/76 erlotinib, docetaxel (2) neutropenia,
leucopenia, anaemia7/F/31 gefitinib, docetaxel (3) leucopenia
The regimen was changed in patients 1–3 [othertreatments not stated; outcomes not stated].
Author comment: "Concerning adverse events of grade 3or higher, they were all hematotoxicity".Hirano S, et al. Efficacy of combination therapy with EGFR-TKI and cytotoxicdrug in lung adenocarcinoma already treated with EGFR-TKI. Gan to KagakuRyoho 39: 213-219, No. 2, Feb 2012 [Japanese; summarised from a translation] -Japan 803074505
1
Reactions 4 Aug 2012 No. 14130114-9954/10/1413-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
